<DOC>
	<DOCNO>NCT01668017</DOCNO>
	<brief_summary>This two-part trial . `` Solid tumor '' protocol mean solid tumor exclude hepatocellular carcinoma ( HCC ) . Part 1 : Dose Escalation Phase subject solid tumor ( Cohort A ) HCC ( Cohort B ) . The dose increase 45 mg twice day ( BID ) 3+3 cohort method recommend phase 2 dose ( RP2D ) pimasertib establish single agent global study arm independently . Part 2 : The Maximum Tolerated Dose ( MTD ) define Part 1 confirm subject Cohort A ( N=18 ) Cohort B ( N=6 ) separately . Following recommendation Safety Monitoring Committee , Cohort B discontinue due hepatocellular carcinoma ( HCC ) enrollment subject cohort . This decision base upon review safety efficacy information .</brief_summary>
	<brief_title>A Multicentre , Open Label , Phase 1 Trial Japan Mitogen Activated Protein Extracellular Signal Regulated Kinase ( MEK ) Inhibitor Pimasertib Given Orally Subjects With Solid Tumors Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Cohort A : A histologically cytologically confirm diagnosis advance solid tumor either refractory standard therapy disease effective standard therapy available . Archived tumor tissue available biopsy tumor tissue need perform . Cohort B : A histologically cytologically confirm diagnosis advance hepatocellular carcinoma ( HCC ) either refractory standard therapy disease effective standard therapy available . Archived tumor tissue available biopsy tumor tissue need perform . Subjects Child Pugh A . Male female Japanese , age great equal ( &gt; = ) 18 year . Subject read understands informed consent form willing able give inform consent . The subject fully understand requirement trial willing comply trial visit assessment . Women childbearing potential must negative blood pregnancy test screen visit . Female subject childbearing potential male subject female partner childbearing potential must willing avoid pregnancy use adequate method contraception 2 week prior , four week last dose investigational medicinal product ( IMP ) . Life expectancy least 3 month Hematological abnormality Cohort A : Hematological test abnormality Hemoglobin &lt; 9.0 g/dL , Neutrophil count &lt; 1.0*10^9/L Platelet count &lt; 100*10^9/L . Cohort B : Hematological test abnormality Hemoglobin &lt; 9.0 g/dL , Neutrophil count &lt; 1.0*10^9/L , Platelet count &lt; 75*10^9/L , subject hepatic encephalopathy Renal impairment evidence serum creatinine &gt; 1.5*upper limit normal ( ULN ) , calculate creatinine clearance &lt; 60 mL/min CockcroftGault formula . Liver function abnormality Total Bilirubin &gt; 1.5*ULN , aspartate transaminase 9AST ) alkaline phosphatase ( ALT ) &gt; 2.5*ULN . For subject HCC liver involvement AST/ALT &gt; 5*ULN . History central nervous system ( CNS ) metastases , unless subject previously treat CNS metastases History difficulty swallowing , malabsorption chronic gastrointestinal disease condition Eastern Cooperative Oncology Group Performance status ( ECOG PS ) great 1 . Has receive chemotherapy , immunotherapy , hormonal therapy , biologic therapy , anticancer therapy ( include investigational agent ) surgical intervention within 28 day 5 half life noncytotoxics registration . Baseline correct QT interval screen ECG ( QTc ) &gt; = 480 m leave ventricular ejection fraction ( LVEF ) &lt; 40 % screen echocardiogram Cohort B : Subjects hepatic encephalopathy , remarkable ascites subject history esophageal varix rupture within 6 month ( subject symptom improvement treatment eligible ) Other serious illness medical condition . Retinal degenerative disease . Previous treatment MEK inhibitor . Legal incapacity limit legal capacity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>cancer , liver</keyword>
</DOC>